Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Coleman

Showing results (831-840 of 898) with videos related to

Pageof 90
Sort By:
American Journal of Surgery|August 8, 2022
Patient characteristics and diagnostic tests associated with syncopal falls: A Southwestern surgical congress multicenter studyJanet S Lee, Abid D Khan, Christopher M Quinn, et al.
Blood|March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLH Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Blood|August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancyPeter G Miller, Adam S Sperling, Christina Mayerhofer, et al.
Blood Advances|July 21, 2019
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantationMax Jan, Matthew J Leventhal, Elizabeth A Morgan, et al.
Blood Advances|March 22, 2023
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditionsAmy E DeZern, Johannes B Goll, R Coleman Lindsley, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDSNurefsan E Sariipek, Ksenia R Safina, Wesley S Lu, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Science (New York, N.Y.)|August 10, 2019
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignanciesSteffen Boettcher, Peter G Miller, Rohan Sharma, et al.
Blood|May 21, 2021
The clinical and functional effects of TERT variants in myelodysplastic syndromeChristopher R Reilly, Mikko Myllymäki, Robert Redd, et al.
Pageof 90

Showing results (831-840 of 898) with videos related to

Sort By:
Pageof 90
American Journal of Surgery|August 8, 2022
Patient characteristics and diagnostic tests associated with syncopal falls: A Southwestern surgical congress multicenter studyJanet S Lee, Abid D Khan, Christopher M Quinn, et al.
Blood|March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLH Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Blood|August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancyPeter G Miller, Adam S Sperling, Christina Mayerhofer, et al.
Blood Advances|July 21, 2019
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantationMax Jan, Matthew J Leventhal, Elizabeth A Morgan, et al.
Blood Advances|March 22, 2023
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditionsAmy E DeZern, Johannes B Goll, R Coleman Lindsley, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDSNurefsan E Sariipek, Ksenia R Safina, Wesley S Lu, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Science (New York, N.Y.)|August 10, 2019
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignanciesSteffen Boettcher, Peter G Miller, Rohan Sharma, et al.
Blood|May 21, 2021
The clinical and functional effects of TERT variants in myelodysplastic syndromeChristopher R Reilly, Mikko Myllymäki, Robert Redd, et al.
Pageof 90